Oh, annual shareholder meetings are probably not going to give you any kind of signal one way or the other. It would be interesting to see a presentation at the ASGT meeting, but those are for biotech research scientists--they certainly don't let in just anybody! And I don't know my wild type from my helper virus anyway. Just happen to hold shares and can read like you. I am glad to see somebody else on the thread with some enthusiasm. Holding a little biotech like this for me is really just gut feel and faith. Oh, it was nice when Parker would promise "we will have products", but smarter to have toned that down. Who can say til the FDA has their day, and that is a few years away. Funny how the clinical development arrows just seem to creep across the graphic, stuck in phase I or II.
What I do especially like about Tgen is the number of collaborations with big names--and enough cash to get through 2003, so they say, that isn't too bad. I can live with just those things and understanding none of the scientific aspects.
Avigen worries me from time to time, they are good spin doctors--and maybe they'll be the AAV winners, who can say.
I've no idea what the Alkermes alliance from '99 did for Tgen, or for that matter what Genovo does for them now. I was excited when the deal went down--but I wish Wilson wasn't doing lentivirus papers etc--and he also seemed to bash AAV2 in the NatureBiotech paper a couple months ago. What was that about.
Sometimes I imagine a monster press release. Avigen, Tgen, Vical, Valentis, Ariad--they all miraculously merge simultaneously one night while Wall Street sleeps. Not holding my breath--nobody wants to give up their job or fire anybody and maybe nobody should have to (I can say that, lucky timing and some profits taken mean that all of my biotechs NET cost me $0. You may have a right to feel differently--if so, raise hell at the next meeting. Scold directors, etc etc. Question the spinoff, whatever. But not me...I'm just riding for free. Carter and Parker seem like good people. I sorta doubt that the row of directors up front does much for them--replace them with a gaggle of new PhD's and you would probably do well. |
